Education Library

Jacob Møller, MD, the principal investigator of the DanGer Shock trial, discusses study results he presented at ACC 2024.

Mir B Basir, DO, discusses the impact of the DanGer Shock RCT in clinical practice, and looks into the future of AMI cardiogenic shock treatment and management.

The NCSI (National Cardiogenic Shock Initiative) assessed the feasibility of using a shock protocol and in-hospital survival in patients with acute myocardial infarction complicated by cardiogenic shock (AMI-CS).

Arkadiusz Pietrasik, MD, PhD, and Aleksandra Gąsecka, MD, PhD discuss their recently published findings from the IMPELLA-PL registry in Poland.

Professor Giuseppe Tarantini discusses timing and treatment strategies for cardiogenic shock.

Prof. Norman Mangner, M.D., discusses the key messages of “From Patient Selection to Escalation Strategies: Mechanical Circulatory Support in Cardiogenic Shock.” published in the European Heart Journal Supplements.

This article examines current evidence for the use of mechanical circulatory support (MCS) in cardiogenic shock and discusses how the scientific community can advance research in this area. 

Letizia Bertoldi, MD, discusses practical management of inotropes in cardiogenic shock as well as an algorithm for mechanical circulatory support selection.

Andrea Montisci, M.D., discusses criteria for planning the appropriate therapeutic approach and predicting outcomes in patients with cardiogenic shock.

“Monitoring is the cornerstone of success in managing cardiogenic shock,” Professor Christophe Vandenbriele, M.D., emphasizes in this discussion of his recently published paper, “Monitoring on the ICU: Integrating Hemodynamic Assessment, Laboratory Data, and Imaging Techniques for Timely Detectio

Dr. Benedikt Schrage, MD, discusses the rationale and indications for ECMELLA (VA ECMO + Impella®) in patients with cardiogenic shock.

Alexander Bernhardt, MD, discusses insertion, escalation, de-escalation, and weaning of MCS devices in patients with cardiogenic shock.

This article describes escalation and weaning best practices for patients with cardiogenic shock supported with ECMELLA—a combination of Impella and extracorporeal membrane oxygenation (ECMO).

“The decision to escalate, de-escalate or wean is highly dependent on patient presentation, capabilities of the institution, and the expertise of the heart team,” write the authors of this paper on differential usage of Impella devices, extracorporeal membrane oxygenation (ECMO), and combined str

In this paper the authors discuss best practices for monitoring CS patients supported by a microaxial flow pump (mAFP) such as Impella®, venoarterial extracorporeal membrane oxygenation (VA ECMO), or both devices together, a combination referred to as ECpella.